Related Experiment Videos
Preclinical evaluation of brimonidine
1Department of Biological Sciences, Allergan, Inc., Irvine, California, USA.
Survey of Ophthalmology
|November 1, 1996
Summary
Brimonidine, a selective alpha 2-adrenoceptor agonist, effectively lowers intraocular pressure (IOP) by reducing aqueous humor flow and enhancing outflow. It also demonstrates neuroprotective properties, making it a promising antiglaucoma agent.
Area of Science:
- Ophthalmology
- Pharmacology
- Neuroscience
Background:
- Brimonidine is a potent alpha 2-adrenoceptor agonist with high selectivity over alpha 1-adrenoceptors.
- Its selectivity surpasses that of clonidine and apraclonidine.
Purpose of the Study:
- To evaluate the efficacy and safety of brimonidine as an antiglaucoma agent.
- To investigate the mechanisms underlying brimonidine's intraocular pressure (IOP)-lowering effects.
- To assess brimonidine's neuroprotective potential in optic nerve injury models.
Main Methods:
- Preclinical studies in various animal models.
- Assessment of adrenoceptor selectivity and IOP reduction.
- Pharmacological characterization of IOP response mechanisms.
- Evaluation of ocular and systemic toxicity.
- Neuroprotection assays following optic nerve injury.
Main Results:
- Brimonidine significantly decreased IOP in animal models without causing mydriasis.
- The IOP-lowering effect involves suppression of aqueous humor flow and enhanced uveoscleral outflow.
- Ocular alpha 2-adrenoceptors and CNS imidazoline receptors mediate the IOP response depending on species.
- Brimonidine achieved adequate drug levels in the posterior segment and showed no vasoconstriction in retinal microvasculature.
- Brimonidine demonstrated neuroprotective effects on the optic nerve and was found to be non-toxic.
Conclusions:
- Brimonidine exhibits high alpha 2-adrenoceptor selectivity and potent ocular hypotensive efficacy.
- Its retinal bioavailability, neuroprotective properties, and favorable safety profile support its use as an antiglaucoma agent.